Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand to Report Second Quarter 2019 Results on July 30th

Read More

Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

Read More

Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range